Keytruda: A New Era of Cancer Care in the UK (2026)
In the rapidly evolving landscape of oncology, Keytruda (pembrolizumab) has transitioned from a "breakthrough" drug to a cornerstone of immunotherapy in the UK. As of early 2026, its role within the NHS has expanded significantly, offering hope to thousands of patients across a widening spectrum of cancer types.
The Mechanism: Unmasking the Enemy
Keytruda is a type of checkpoint inhibitor. It works by targeting the PD-1 pathway, a mechanism that some cancer cells use to "hide" from the immune system. By blocking this protein, the drug effectively pulls back the veil, allowing the body’s own T-cells to recognize and destroy the malignant cells.
Expanded NHS Access and New Milestones
The National Institute for Health and Care Excellence (NICE) has been prolific in its recent approvals. Moving into 2026, Keytruda is no longer just for advanced melanoma or non-small cell lung cancer (NSCLC). Key updates include:
Endometrial Cancer: In late 2025, NICE approved the first-line use of Keytruda in combination with chemotherapy for primary advanced or recurrent endometrial cancer, marking a major shift in how womb cancers are treated.
Cervical Cancer: Following successful data from the Cancer Drugs Fund (CDF), it has become a standard life-extending option for patients with incurable cervical cancer.
Adjuvant Success: The drug is increasingly used in the adjuvant setting—given after surgery to reduce the risk of the cancer returning in patients with high-risk melanoma and certain lung cancers.
Administration and Patient Life
Treatment is typically administered via an intravenous (IV) infusion every three or six weeks, depending on the dosage plan. While it avoids the traditional side effects of chemotherapy (like hair loss), it introduces "immune-related" side effects. Because the drug ramps up the immune system, it can occasionally cause inflammation in healthy organs, such as the lungs (pneumonitis), thyroid, or bowel (colitis).